ClinicalTrials.gg
CompletedNCT01299805Updated Dec 13, 2013Results posted

Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults

A Phase 1 interventional study of Vortioxetine and Placebo in Healthy, sponsored by Takeda. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-12-13.

Sponsored by Takeda · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The purpose of this study is to evaluate the pharmacodynamics (the drug's effect on the body), the pharmacokinetics (the body's handling of the drug), and the safety and tolerability of vortioxetine, once daily (QD) in healthy men.

Read the detailed description

This study will look at an investigational medicine called vortioxetine to see how the drug affects the body and how the body handles the drug.

The study enrolled 17 patients. Participants were randomly assigned at a 2:1 ratio to one of the following two treatment groups-which remained undisclosed to both the participant and study doctor during the study (unless there was an urgent medical need):

  • Vortioxetine 20 mg
  • Placebo (dummy inactive pill) - this was a capsule that looked like the study drug but had no active ingredient.

All participants were asked to take one capsule at the same time each day throughout the study.

This single-center trial was conducted in the United States. The overall time to participate in this study was approximately 7 weeks. Participants made 2 visits to the clinic, including 18 days confinement to the clinic, and were contacted by telephone 1 day and 27 days after leaving confinement for a follow-up assessment.

02

Conditions studied

  • Healthy

Keywords

  • Drug Therapy
  • pharmacodynamic
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Weighs at least 50 kg and has a between 19.0 and 32.0 kg/m\^2, inclusive at Screening.
  • Males who are nonsterilized and sexually active with a female partner of must agrees to use adequate from signing of throughout the duration of the study and for 6 weeks after last dose of study medication. The acceptable method of contraception is defined as one that has no higher than a 1% failure rate.

Exclusion criteria

Exclusion Criteria:

  • Received any compound within 45 days prior to Check-in (Day -2).
  • Received Lu AA21004 in previous clinical study or as therapeutic agent.
  • History of or uncontrolled, neurologic, cardiovascular, pulmonary, central nervous system, hepatic hematopoietic disease, renal metabolic, gastrointestinal, or endocrine disease, serious allergy, asthma, hypoxemia, hypertension, seizures, allergic skin rash or other abnormality, which may impact the ability of the participant to participate or potentially confound study results.
  • Participant has 1 or more of the following:

    • Any current psychiatric disorder as defined in the , Fourth Edition Text Revision (DSM-IV-TR).
    • Current or history of: manic or hypomanic episode, schizophrenia or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.
    • Presence or history of a clinically significant neurological disorder (including epilepsy).
    • Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc).
    • Any Axis II disorder.
  • Has a known to any component of the formulation of Lu AA21004.
  • Has a positive urine drug result for drugs of abuse at Screening or Check-in (Day -2).
  • Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse (defined as regular consumption of 4 or more units per day) within 1 year prior to the Screening visit or is unwilling to agree to abstain from alcohol and drugs throughout the study. One unit is equivalent to a half-pint of beer or 1 measure of spirits or 1 glass of wine.
  • The participant intends to impregnate or donate sperm during the course of this study or for 6 weeks after last dose.
  • Has current or recent (within 6 months) gastrointestinal disease that would be expected to influence the absorption of drugs (e.g., a history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis; frequent (more than once per week) occurrence of heartburn, or any intra-abdominal surgery (except laparoscopic cholecystectomy or uncomplicated appendectomy).
  • Has a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin that has not been in remission for at least 5 years prior to Day 1.
  • Has a positive test result for surface antigen (HBsAg), antibody at Screening or a known history of infection.
  • Has used nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) within 28 days prior to Check-in (Day -2) or is unwilling to abstain from these products for the duration of the study.
  • Cotinine test is positive at Screening or Check-in (Day 2).
  • Has poor peripheral venous access.
  • Has donated or lost 450 mL or more of his blood volume (including plasmapheresis), or had a transfusion of any blood product within 30 days prior to Day 1.
  • Has a Screening or Check-in (Day -2) abnormal (clinically significant) (ECG). Entry of any patient with an abnormal (not clinically significant) ECG must be approved, and documented by signature by the principal investigator.
  • Has abnormal Screening or Day -2 laboratory values that suggest a clinically significant underlying disease or with the following lab abnormalities: and/or aspartate aminotransferase >1.5 times the .
  • Has had cerebrospinal fluid (CSF) collection performed within 30 days prior to Check-in (Day -2).
  • Has taken any selective serotonin reuptake inhibitor (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), or monoamine oxidase inhibitors, antipsychotics, tricyclic antidepressants, or mood stabilizers within the last year prior to Screening.
  • Has a known hypersensitivity to the anesthetic or its derivatives used during CSF collection, or any medication used to prepare the area of lumbar puncture.
  • Has significant vertebral deformities (scoliosis or kyphosis) which, in the opinion of the investigator, may interfere with lumbar puncture procedure.
  • Has a history of clinically significant back pain and/or injury.
  • Has local infection at the puncture site.
  • Has a history of significant bleeding or coagulation disorder and/or low levels (\<130x10\^9/L) or increased (INR) (>1.3) at Screening.
  • Answers positive to any suicidal ideation and/or suicidal behavior questions during administration of the Columbia-Suicide Severity Rating Scale.
  • Has an orthostatic blood pressure drop of ≥20 mm Hg (based on the drop between supine and standing [3 minutes] systolic blood pressure) at Screening or Check-in (Day -2).
  • Has abnormal Screening or Day -2 vital signs: resting systolic blood pressure ≤90 or ≥140 mm Hg or a resting diastolic blood pressure ≤50 or ≥90 mm Hg in supine position; resting pulse or heart rate (as read on ECG) \<45 bpm or >100 bpm. No more than 2 repeat measurements.
  • Exercises extensively in his normal life (e.g., marathon running, triathlon, physical sports at a contest level etc).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Vortioxetine

    Vortioxetine 20 mg, encapsulated tablet, orally, once daily for up to 14 days.

    Drug: Vortioxetine

  • Placebo comparator
    Placebo

    Vortioxetine placebo-matching capsules, orally, once daily for up to 14 days.

    Drug: Placebo

Interventions

  • Encapsulated tablet

    Also known as: Lu AA21004, Brintellix

  • DrugPlacebo

    Vortioxetine placebo-matching capsules.

06

What researchers measure

Primary outcomes

  1. Area Under the Effect Curve From Time Zero to 24 Hours Postdose of 5-hydroxytryptamine (5-HT) in Plasma

    The area under the effect-time curve from time 0 to 24 hours postdose (AUEC\[0-24\]) of the neurotransmitter 5-HT (serotonin) in plasma was measured at Baseline, after a single dose (Day 1) and after multiple doses (Day 14).

    Time frame: Day -1 (Baseline), Day 1 and Day 14. Blood samples were taken predose (up to 15 minutes prior) and at 1, 2, 4, 8, 12, 16 and 24 hours post-dose.

  2. Maximum Concentration of 5-HT in Plasma

    The maximum observed effect (Emax), assessed by the maximum observed concentration of 5-HT in plasma measured at Baseline, after a single dose (Day 1) and after multiple doses (Day 14).

    Time frame: Day -1 (Baseline), Day 1 and Day 14. Blood samples were taken predose (up to 15 minutes prior) and at 1, 2, 4, 8, 12, 16 and 24 hours post-dose.

  3. Time to Maximum Concentration of 5-HT in Plasma

    The time to reach maximum pharmacodynamic effect (Emax) was assessed by the time to maximum concentration of 5-HT in plasma at Baseline, after a single dose (Day 1) and after multiple doses (Day 14).

    Time frame: Day -1 (Baseline), Day 1 and Day 14. Blood samples were taken predose and at 1, 2, 4, 8, 12, 16, and 24 hours postdose.

  4. Area Under the Effect Curve From Time Zero to 24 Hours Postdose of 5-HT in Cerebrospinal Fluid

    The area under the effect-time curve from time 0 to 24 hours postdose (AUEC\[0-24\]) of 5-hydroxytryptamine (5-HT) in cerebrospinal fluid (CSF) was measured at Baseline, after a single dose (Day 1) and after multiple doses (Day 14).

    Time frame: Day -1 (Baseline), Day 1 and Day 14. CSF samples were taken prior to dose and at 1, 2, 4, 8, 12, 16, and 24 hours postdose.

  5. Maximum Concentration of 5-HT in Cerobrospinal Fluid

    The maximum observed effect (Emax), assessed by the maximum concentration of 5-HT in cerebrospinal fluid (CSF) measured at Baseline, after a single dose (Day 1) and after multiple doses (Day 14).

    Time frame: Day -1 (Baseline), Day 1 and Day 14. CSF samples were taken prior to dose and at 1, 2, 4, 8, 12, 16, and 24 hours postdose.

  6. Time to Maximum Concentration of 5-HT in Cerebrospinal Fluid

    The time to reach maximum pharmacodynamic effect (Emax) was assessed by the time to maximum concentration of 5-HT in cerebrospinal fluid (CSF) at Baseline, after a single dose (Day 1) and after multiple doses (Day 14).

    Time frame: Day -1, Day 1 and Day 14. CSF samples were taken predose and at 1, 2, 4, 8, 12, 16, and 24 hours postdose.

  7. Area Under the Effect Curve From Time Zero to 24 Hours Postdose of 5-hydroxyindoleacetic Acid (5-HIAA) in Plasma

    Area under the effect-time curve from time 0 to 24 hours postdose (AUEC\[0-24\]) of 5-HIAA, a metabolite of the neurotransmitter serotonin, in plasma was measured after a single dose (Day 1) and after multiple doses (Day 14). Note: Plasma samples for 5-HIAA on Day -1 were lost in shipping. Therefore, no PD parameters were calculated for Day -1.

    Time frame: Day 1 and Day 14. Blood samples were taken predose and at 1, 2, 4, 8, 12, 16 and 24 hours post-dose.

  8. Maximum Concentration of 5-HIAA in Plasma

    The maximum observed effect (Emax), assessed by the maximum observed concentration of 5-HIAA in plasma measured after a single dose (Day 1) and after multiple doses (Day 14). Note: Plasma samples for 5-HIAA on Day -1 were lost in shipping. Therefore, no PD parameters were calculated for Day -1

    Time frame: Day 1 and Day 14. Blood samples were taken predose (up to 15 minutes prior) and at 1, 2, 4, 8, 12, 16 and 24 hours post-dose.

  9. Time to Maximum Concentration of 5-HIAA in Plasma

    The time to reach maximum pharmacodynamic effect (Emax) was assessed by the time to maximum concentration of 5-hydroxyindoleacetic acid (5-HIAA) in plasma after a single dose (Day 1) and after multiple doses (Day 14). Note: Plasma samples for 5-HIAA on Day -1 were lost in shipping. Therefore, no PD parameters were calculated for Day -1.

    Time frame: Day 1 and Day 14. Blood samples were taken predose and at 1, 2, 4, 8, 12, 16 and 24 hours post-dose.

  10. Area Under the Effect Curve From Time Zero to 24 Hours Postdose of 5-HIAA in Cerebrospinal Fluid

    The area under the effect-time curve from time 0 to 24 hours postdose (AUEC\[0-24\]) of 5-hydroxyindoleacetic acid (5-HIAA) in cerebrospinal fluid (CSF) was measured at Baseline, after a single dose (Day 1) and after multiple doses (Day 14).

    Time frame: Day -1 (Baseline), Day 1 and Day 14. CSF samples were taken prior to dose and at 1, 2, 4, 8, 12, 16, and 24 hours postdose.

  11. Maximum Concentration of 5-HIAA in Cerebrospinal Fluid

    The maximum observed effect (Emax), assessed by the maximum observed concentration of 5-HIAA in cerebrospinal fluid (CSF) measured at Baseline, after a single dose (Day 1) and after multiple doses (Day 14).

    Time frame: Day -1 (Baseline), Day 1 and Day 14. CSF samples were taken prior to dose and at 1, 2, 4, 8, 12, 16, and 24 hours postdose.

  12. Time to Maximum Concentration of 5-HIAA in Cerebrospinal Fluid

    The time to reach maximum pharmacodynamic effect (Emax) was assessed by the time to maximum concentration of 5-hydroxyindoleacetic acid (5-HIAA) in cerebrospinal fluid (CSF) at Baseline, after a single dose (Day 1) and after multiple doses (Day 14).

    Time frame: Day -1, Day 1 and Day 14. CSF samples were taken prior to dose and at 1, 2, 4, 8, 12, 16, and 24 hours postdose.

07

Results

Posted Dec 13, 2013

Participant flow

Participants took part in the study at one investigative site in the United States from 14 March 2011 to 11 June 2011.

Participant flow — Overall Study
MilestoneVortioxetinePlacebo
Started125
Completed105
Not completed20
Withdrew: Adverse event20

Outcome measures

PrimaryArea Under the Effect Curve From Time Zero to 24 Hours Postdose of 5-hydroxytryptamine (5-HT) in Plasma

The area under the effect-time curve from time 0 to 24 hours postdose (AUEC\[0-24\]) of the neurotransmitter 5-HT (serotonin) in plasma was measured at Baseline, after a single dose (Day 1) and after multiple doses (Day 14).

Time frame:
Day -1 (Baseline), Day 1 and Day 14. Blood samples were taken predose (up to 15 minutes prior) and at 1, 2, 4, 8, 12, 16 and 24 hours post-dose.
Reported as:
Mean · pg*hr/mL
Area Under the Effect Curve From Time Zero to 24 Hours Postdose of 5-hydroxytryptamine (5-HT) in Plasma
pg*hr/mLVortioxetinePlacebo
Day -1 (n=10, 4)4183024 ± 13621353854399 ± 1728230
Day 1 (n=6, 4)4224058 ± 20288353912292 ± 2083773
Day 14 (n=9, 5)1718863 ± 5306333858350 ± 2212719
PrimaryMaximum Concentration of 5-HT in Plasma

The maximum observed effect (Emax), assessed by the maximum observed concentration of 5-HT in plasma measured at Baseline, after a single dose (Day 1) and after multiple doses (Day 14).

Time frame:
Day -1 (Baseline), Day 1 and Day 14. Blood samples were taken predose (up to 15 minutes prior) and at 1, 2, 4, 8, 12, 16 and 24 hours post-dose.
Reported as:
Mean · pg/mL
Maximum Concentration of 5-HT in Plasma
pg/mLVortioxetinePlacebo
Day -1 (n=10, 4)273800 ± 111197231500 ± 98083.3
Day 1 (n=6, 4)247667 ± 136695251250 ± 63615.4
Day 14 (n=9, 5)94233.3 ± 40258.4242200 ± 115103
PrimaryTime to Maximum Concentration of 5-HT in Plasma

The time to reach maximum pharmacodynamic effect (Emax) was assessed by the time to maximum concentration of 5-HT in plasma at Baseline, after a single dose (Day 1) and after multiple doses (Day 14).

Time frame:
Day -1 (Baseline), Day 1 and Day 14. Blood samples were taken predose and at 1, 2, 4, 8, 12, 16, and 24 hours postdose.
Reported as:
Mean · hours
Time to Maximum Concentration of 5-HT in Plasma
hoursVortioxetinePlacebo
Day -1 (n=10, 4)12.65 ± 9.4097.26 ± 7.984
Day 1 (n=6, 4)4.86 ± 7.25314.42 ± 11.146
Day 14 (n=9, 5)9.11 ± 10.0808.40 ± 6.986
PrimaryArea Under the Effect Curve From Time Zero to 24 Hours Postdose of 5-HT in Cerebrospinal Fluid

The area under the effect-time curve from time 0 to 24 hours postdose (AUEC\[0-24\]) of 5-hydroxytryptamine (5-HT) in cerebrospinal fluid (CSF) was measured at Baseline, after a single dose (Day 1) and after multiple doses (Day 14).

Time frame:
Day -1 (Baseline), Day 1 and Day 14. CSF samples were taken prior to dose and at 1, 2, 4, 8, 12, 16, and 24 hours postdose.
Reported as:
Mean · pg*hr/mL
Area Under the Effect Curve From Time Zero to 24 Hours Postdose of 5-HT in Cerebrospinal Fluid
pg*hr/mLVortioxetinePlacebo
Day -1 (n=11, 5)987.71 ± 1898.943509.77 ± 199.658
Day 1 (n=11, 5)627.78 ± 164.679497.40 ± 302.720
Day 14 (n=9, 5)1165.73 ± 290.389444.88 ± 24.908
PrimaryMaximum Concentration of 5-HT in Cerobrospinal Fluid

The maximum observed effect (Emax), assessed by the maximum concentration of 5-HT in cerebrospinal fluid (CSF) measured at Baseline, after a single dose (Day 1) and after multiple doses (Day 14).

Time frame:
Day -1 (Baseline), Day 1 and Day 14. CSF samples were taken prior to dose and at 1, 2, 4, 8, 12, 16, and 24 hours postdose.
Reported as:
Mean · pg/mL
Maximum Concentration of 5-HT in Cerobrospinal Fluid
pg/mLVortioxetinePlacebo
Day -1 (n=11, 5)116.60 ± 293.72167.74 ± 94.396
Day 1 (n=11, 5)35.46 ± 13.17224.10 ± 14.030
Day 14 (n=9, 5)59.80 ± 16.52451.46 ± 33.647
PrimaryTime to Maximum Concentration of 5-HT in Cerebrospinal Fluid

The time to reach maximum pharmacodynamic effect (Emax) was assessed by the time to maximum concentration of 5-HT in cerebrospinal fluid (CSF) at Baseline, after a single dose (Day 1) and after multiple doses (Day 14).

Time frame:
Day -1, Day 1 and Day 14. CSF samples were taken predose and at 1, 2, 4, 8, 12, 16, and 24 hours postdose.
Reported as:
Mean · hours
Time to Maximum Concentration of 5-HT in Cerebrospinal Fluid
hoursVortioxetinePlacebo
Day -1 (n=11, 5)4.30 ± 5.8907.13 ± 10.624
Day 1 (n=11, 5)17.32 ± 7.1776.92 ± 8.225
Day 14 (n=9, 5)3.02 ± 3.5764.94 ± 6.964
PrimaryArea Under the Effect Curve From Time Zero to 24 Hours Postdose of 5-hydroxyindoleacetic Acid (5-HIAA) in Plasma

Area under the effect-time curve from time 0 to 24 hours postdose (AUEC\[0-24\]) of 5-HIAA, a metabolite of the neurotransmitter serotonin, in plasma was measured after a single dose (Day 1) and after multiple doses (Day 14). Note: Plasma samples for 5-HIAA on Day -1 were lost in shipping. Therefore, no PD parameters were calculated for Day -1.

Time frame:
Day 1 and Day 14. Blood samples were taken predose and at 1, 2, 4, 8, 12, 16 and 24 hours post-dose.
Reported as:
Mean · ng*hr/mL
Area Under the Effect Curve From Time Zero to 24 Hours Postdose of 5-hydroxyindoleacetic Acid (5-HIAA) in Plasma
ng*hr/mLVortioxetinePlacebo
Day 1 (n=12, 5)140.01 ± 23.633145.92 ± 28.844
Day 14 (n=10, 5)143.69 ± 30.049140.40 ± 25.305
PrimaryMaximum Concentration of 5-HIAA in Plasma

The maximum observed effect (Emax), assessed by the maximum observed concentration of 5-HIAA in plasma measured after a single dose (Day 1) and after multiple doses (Day 14). Note: Plasma samples for 5-HIAA on Day -1 were lost in shipping. Therefore, no PD parameters were calculated for Day -1

Time frame:
Day 1 and Day 14. Blood samples were taken predose (up to 15 minutes prior) and at 1, 2, 4, 8, 12, 16 and 24 hours post-dose.
Reported as:
Mean · ng/mL
Maximum Concentration of 5-HIAA in Plasma
ng/mLVortioxetinePlacebo
Day 1 (n=12, 5)7.25 ± 1.1136.97 ± 1.282
Day 14 (n=10, 5)6.90 ± 1.4027.10 ± 1.301
PrimaryTime to Maximum Concentration of 5-HIAA in Plasma

The time to reach maximum pharmacodynamic effect (Emax) was assessed by the time to maximum concentration of 5-hydroxyindoleacetic acid (5-HIAA) in plasma after a single dose (Day 1) and after multiple doses (Day 14). Note: Plasma samples for 5-HIAA on Day -1 were lost in shipping. Therefore, no PD parameters were calculated for Day -1.

Time frame:
Day 1 and Day 14. Blood samples were taken predose and at 1, 2, 4, 8, 12, 16 and 24 hours post-dose.
Reported as:
Mean · hours
Time to Maximum Concentration of 5-HIAA in Plasma
hoursVortioxetinePlacebo
Day 1 (n=12, 5)13.02 ± 10.99215.13 ± 9.886
Day 14 (n=10, 5)16.80 ± 7.00518.40 ± 5.367
PrimaryArea Under the Effect Curve From Time Zero to 24 Hours Postdose of 5-HIAA in Cerebrospinal Fluid

The area under the effect-time curve from time 0 to 24 hours postdose (AUEC\[0-24\]) of 5-hydroxyindoleacetic acid (5-HIAA) in cerebrospinal fluid (CSF) was measured at Baseline, after a single dose (Day 1) and after multiple doses (Day 14).

Time frame:
Day -1 (Baseline), Day 1 and Day 14. CSF samples were taken prior to dose and at 1, 2, 4, 8, 12, 16, and 24 hours postdose.
Reported as:
Mean · ng*hr/mL
Area Under the Effect Curve From Time Zero to 24 Hours Postdose of 5-HIAA in Cerebrospinal Fluid
ng*hr/mLVortioxetinePlacebo
Day -1 (n=12, 5)620.61 ± 182.391718.14 ± 247.082
Day 1 (n=12, 5)636.14 ± 246.071774.95 ± 319.860
Day 14 (n=9, 5)429.23 ± 99.575644.24 ± 206.121
PrimaryMaximum Concentration of 5-HIAA in Cerebrospinal Fluid

The maximum observed effect (Emax), assessed by the maximum observed concentration of 5-HIAA in cerebrospinal fluid (CSF) measured at Baseline, after a single dose (Day 1) and after multiple doses (Day 14).

Time frame:
Day -1 (Baseline), Day 1 and Day 14. CSF samples were taken prior to dose and at 1, 2, 4, 8, 12, 16, and 24 hours postdose.
Reported as:
Mean · ng/mL
Maximum Concentration of 5-HIAA in Cerebrospinal Fluid
ng/mLVortioxetinePlacebo
Day -1 (n=12, 5)29.87 ± 8.23134.30 ± 12.270
Day 1 (n=12, 5)31.13 ± 9.56736.98 ± 18.346
Day 14 (n=9, 5)20.18 ± 4.93530.16 ± 8.768
PrimaryTime to Maximum Concentration of 5-HIAA in Cerebrospinal Fluid

The time to reach maximum pharmacodynamic effect (Emax) was assessed by the time to maximum concentration of 5-hydroxyindoleacetic acid (5-HIAA) in cerebrospinal fluid (CSF) at Baseline, after a single dose (Day 1) and after multiple doses (Day 14).

Time frame:
Day -1, Day 1 and Day 14. CSF samples were taken prior to dose and at 1, 2, 4, 8, 12, 16, and 24 hours postdose.
Reported as:
Mean · hours
Time to Maximum Concentration of 5-HIAA in Cerebrospinal Fluid
hoursVortioxetinePlacebo
Day -1 (n=12, 5)14.16 ± 10.71019.78 ± 8.877
Day 1 (n=12, 5)6.24 ± 8.96019.00 ± 10.621
Day 14 (n=9, 5)11.70 ± 10.5769.90 ± 9.592

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vortioxetine—0/12 (0%)11/12 (91.7%)
Placebo—0/5 (0%)4/5 (80%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventVortioxetinePlacebo
Post lumbar puncture syndromeInjury, poisoning and procedural complications6/122/5
Back painMusculoskeletal and connective tissue disorders6/120/5
NauseaGastrointestinal disorders5/120/5
VomitingGastrointestinal disorders4/120/5
HeadacheNervous system disorders4/121/5
MyalgiaMusculoskeletal and connective tissue disorders0/121/5
Chest discomfortGeneral disorders1/120/5
TendernessGeneral disorders1/120/5
Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders1/120/5
DizzinessNervous system disorders1/120/5

Baseline characteristics

Age Continuous
Age Continuous(years)VortioxetinePlaceboTotal
Mean34.3 ± 11.1934.8 ± 10.7134.4 ± 10.71
Sex: Female, Male
Sex: Female, Male(Participants)VortioxetinePlaceboTotal
Female000
Male12517
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)VortioxetinePlaceboTotal
Hispanic or Latino303
Not Hispanic or Latino9514
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)VortioxetinePlaceboTotal
Black or African American314
White9413
Region of Enrollment
Region of Enrollment(participants)VortioxetinePlaceboTotal
United States12517
Height
Height(cm)VortioxetinePlaceboTotal
Mean176.8 ± 5.88175.9 ± 8.15176.6 ± 6.37
Weight
Weight(kg)VortioxetinePlaceboTotal
Mean81.8 ± 8.8479.9 ± 7.5281.3 ± 8.29
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)VortioxetinePlaceboTotal
Mean26.2 ± 2.8525.8 ± 1.9226.1 ± 2.56

4 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Glendale, California, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Jun 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2011
First posted
Feb 18, 2011
Start
Mar 2011
Primary completionActual
Jun 2011
CompletionActual
Jul 2011
Results first posted
Dec 13, 2013
Last update
Dec 13, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01299805
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Feb 18, 2011
Start date
Mar 2011
Primary completion
Jun 2011
Completion
Jul 2011
Results posted
Dec 13, 2013
Last update
Dec 13, 2013

Study contacts

Medical Director, Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion